PHAT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

56.16M

+89.33%

-0.391

-62.72%

59.38M

+108.22%

-0.422

-67.81%

72.18M

+82.73%

-0.293

-72.06%

Estimates Revision

The market is revising Upward the revenue expectations for Phathom Pharmaceuticals, Inc. (PHAT) for FY2025, with the revenue forecasts being adjusted by 2.17% over the past three months. During the same period, the stock price has changed by 27.03%.

Revenue Estimates for FY2025

Revise Upward

+2.17%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-4%

In Past 3 Month

Stock Price

Go Up

+27.03%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast PHAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAT is 27.67 USD with a low forecast of 26.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

26.00

Averages

27.67

High

29.00

Current: 0.000

Low

26.00

Averages

27.67

High

29.00

Raymond James

Martin Auster

Strong Buy

initiated

$28

2025-12-11

Reason

Raymond James

Martin Auster

Price Target

$28

2025-12-11

initiated

Strong Buy

Reason

Raymond James analyst Martin Auster initiated coverage of Phathom Pharmaceuticals with a Strong Buy rating and $28 price target. Phathom is commercializing Voquezna, the first and only FDA-approved potassium competitive acid blocker for gastroesophageal reflux disease, with key advantages over existing standard-of-care therapies, the analyst noted. The firm sees an attractive long-term valuation risk/reward with a refocused commercial strategy and "impressive" expense rationalization this year, the analyst tells investors.

Barclays

Jenna Davidner

Equal Weight

initiated

$16

2025-12-08

Reason

Barclays

Jenna Davidner

Price Target

$16

2025-12-08

initiated

Equal Weight

Reason

Barclays analyst Jenna Davidner initiated coverage of Phathom Pharmaceuticals with an Equal Weight rating and $16 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."

Craig-Hallum

Chase Knickerbocker

Buy

maintain

$17 -> $22

2025-10-31

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$17 -> $22

2025-10-31

maintain

Buy

Reason

Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on Phathom Pharmaceuticals to $22 from $17 and keeps a Buy rating on the shares. The firm notes the company delivered a solid beat on both revenue and expense discipline as the company pivots away from direct-to-consumer sales and focuses on GI specialists. FY2025 revenue guidance was raised at the midpoint to $170M-$175M from $165M-$175M, and management reiterated expectations for operating profitability in 2026.

H.C. Wainwright

Buy

upgrade

$20 -> $26

2025-10-31

Reason

H.C. Wainwright

Price Target

$20 -> $26

2025-10-31

upgrade

Buy

Reason

H.C. Wainwright raised the firm's price target on Phathom Pharmaceuticals to $26 from $20 and keeps a Buy rating on the shares following the Q3 report.

Cantor Fitzgerald

NULL

Overweight

upgrade

$23 -> $29

2025-06-06

Reason

Cantor Fitzgerald

Price Target

$23 -> $29

2025-06-06

upgrade

NULL

Overweight

Reason

Cantor Fitzgerald raised the firm's price target on Phathom Pharmaceuticals to $29 from $23 and keeps an Overweight rating on the shares. The FDA has granted Phathom Pharmaceuticals 10-year exclusivity for Voquenza, which extends the exclusivity period to May 2032 instead of 2030, adding about $6 per share to the firm's distributable cash flow estimates, the analyst tells investors in a research note. Cantor says the overhang has been removed and continues to view Voquenza as a "great" drug in the acid-suppression space with more room to grow.

Needham

Joseph Stringer

Strong Buy

Reiterates

$28

2025-04-21

Reason

Needham

Joseph Stringer

Price Target

$28

2025-04-21

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Phathom Pharmaceuticals Inc (PHAT.O) is -12.29, compared to its 5-year average forward P/E of -4.12. For a more detailed relative valuation and DCF analysis to assess Phathom Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.12

Current PE

-12.29

Overvalued PE

-0.85

Undervalued PE

-7.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

4.00

Current EV/EBITDA

177.48

Overvalued EV/EBITDA

40.43

Undervalued EV/EBITDA

-32.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

119.79

Current PS

4.02

Overvalued PS

342.81

Undervalued PS

-103.22

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PHAT News & Events

Events Timeline

No data

News

9.5

01-08Benzinga

PinnedPhathom Pharmaceuticals Sees Q4 Sales of $57-58M, Prices $130M Public Offering

2.0

01-08Benzinga

Northrop Grumman Shares Rise 6.84% Following Military Budget Proposal

9.5

01-08Benzinga

AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%

People Also Watch

Frequently Asked Questions

What is Phathom Pharmaceuticals Inc (PHAT) stock price today?

The current price of PHAT is 15.015 USD — it has decreased -3.75 % in the last trading day.

What is Phathom Pharmaceuticals Inc (PHAT)'s business?

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

What is the price predicton of PHAT Stock?

What is Phathom Pharmaceuticals Inc (PHAT)'s revenue for the last quarter?

Phathom Pharmaceuticals Inc revenue for the last quarter amounts to 49.50M USD, increased 202.74 % YoY.

What is Phathom Pharmaceuticals Inc (PHAT)'s earnings per share (EPS) for the last quarter?

Phathom Pharmaceuticals Inc. EPS for the last quarter amounts to -0.41 USD, decreased -68.94 % YoY.

What changes have occurred in the market's expectations for Phathom Pharmaceuticals Inc (PHAT)'s fundamentals?

How many employees does Phathom Pharmaceuticals Inc (PHAT). have?

Phathom Pharmaceuticals Inc (PHAT) has 427 emplpoyees as of January 10 2026.

What is Phathom Pharmaceuticals Inc (PHAT) market cap?

Today PHAT has the market capitalization of 1.07B USD.